10.05
0.35 (3.61%)
| Previous Close | 9.70 |
| Open | 9.69 |
| Volume | 108,176 |
| Avg. Volume (3M) | 207,290 |
| Market Cap | 366,788,832 |
| Price / Book | 1.16 |
| 52 Weeks Range | |
| Earnings Date | 11 Mar 2025 |
| Diluted EPS (TTM) | -3.78 |
| Total Debt/Equity (MRQ) | 0.48% |
| Current Ratio (MRQ) | 35.34 |
| Operating Cash Flow (TTM) | -64.83 M |
| Levered Free Cash Flow (TTM) | -44.47 M |
| Return on Assets (TTM) | -22.07% |
| Return on Equity (TTM) | -35.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Rapport Therapeutics, Inc. | Mixed | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.33 |
|
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.59% |
| % Held by Institutions | 100.74% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trv Gp V, Llc | 31 Dec 2024 | 7,135,233 |
| Trv Gp Vi, Llc | 31 Dec 2024 | 969,218 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Mar 2025 | Announcement | Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting |
| 11 Mar 2025 | Announcement | Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 03 Mar 2025 | Announcement | Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development |
| 24 Feb 2025 | Announcement | Rapport Therapeutics to Participate in Upcoming Investor Conferences |
| 09 Jan 2025 | Announcement | Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |